Cognition Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Cognition Therapeutics, Inc. (CGTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 1.39 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-07
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-12-31 was 8.59K shares, a 105.06% increase year-over-year.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-09-30 was 0.00 shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-06-30 was 1.18K shares.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 22.04K shares, a 71.96% increase from fiscal 2024.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 12.81K shares, a 84.73% decline from fiscal 2023.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 83.93K shares, a 87.01% decline from fiscal 2022.
- Cognition Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 646.07K shares, a 271.36% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.39K shares 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 22.04K shares 10-K · filed 2026-03-26 | ||
| 2025-09-30 | 22.04K shares 10-Q · filed 2025-11-06 | |||
| 2024-12-31 | 8.59K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | 8.59K shares derived: sum of 2 quarters · filed 2025-03-20 | 9.77K shares derived: sum of 3 quarters · filed 2025-03-20 | 12.81K shares 10-K · filed 2025-03-20 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 1.18K shares derived: sum of 2 quarters · filed 2024-11-13 | 4.22K shares 10-Q · filed 2024-11-13 | 8.41K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 1.18K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 4.22K shares 10-Q · filed 2024-08-08 | 8.41K shares derived: sum of 3 quarters · filed 2024-08-08 | 8.41K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 3.05K shares 10-Q · filed 2024-05-07 | 7.24K shares derived: sum of 2 quarters · filed 2024-05-07 | 7.24K shares derived: sum of 3 quarters · filed 2024-05-07 | |
| 2023-12-31 | 4.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 4.19K shares derived: sum of 2 quarters · filed 2024-03-26 | 83.93K shares 10-K · filed 2024-03-26 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 79.74K shares 10-Q · filed 2023-11-02 | ||
| 2023-06-30 | 79.74K shares 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | 29.74K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 223.20K shares derived: sum of 2 quarters · filed 2023-03-23 | 249.71K shares derived: sum of 3 quarters · filed 2023-03-23 | 646.07K shares 10-K · filed 2023-03-23 |
| 2022-09-30 | 193.46K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 219.97K shares derived: sum of 2 quarters · filed 2022-11-14 | 616.33K shares 10-Q · filed 2022-11-14 | 628.83K shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 26.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 422.87K shares 10-Q · filed 2022-08-09 | 435.37K shares derived: sum of 3 quarters · filed 2022-08-09 | |
| 2022-03-31 | 396.36K shares 10-Q · filed 2022-05-11 | 408.86K shares derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2021-12-31 | 12.49K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 173.97K shares 10-K · filed 2022-03-30 | ||
| 2021-09-30 | 161.48K shares 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |